Mana Capital Acquisition (MAAQ) Competitors $3.64 +0.14 (+4.00%) As of 08/21/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MAAQ vs. PLX, AVTX, CLYM, SAVA, ZURA, CRDL, SPRO, IMRX, LIMN, and ZNTLShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Protalix BioTherapeutics (PLX), Avalo Therapeutics (AVTX), Climb Bio (CLYM), Cassava Sciences (SAVA), Zura Bio (ZURA), Cardiol Therapeutics (CRDL), Spero Therapeutics (SPRO), Immuneering (IMRX), Liminatus Pharma (LIMN), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. Its Competitors Protalix BioTherapeutics Avalo Therapeutics Climb Bio Cassava Sciences Zura Bio Cardiol Therapeutics Spero Therapeutics Immuneering Liminatus Pharma Zentalis Pharmaceuticals Mana Capital Acquisition (NASDAQ:MAAQ) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations. Does the media favor MAAQ or PLX? In the previous week, Protalix BioTherapeutics had 9 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 9 mentions for Protalix BioTherapeutics and 0 mentions for Mana Capital Acquisition. Protalix BioTherapeutics' average media sentiment score of 0.45 beat Mana Capital Acquisition's score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Mana Capital Acquisition Neutral Protalix BioTherapeutics Neutral Which has stronger earnings and valuation, MAAQ or PLX? Protalix BioTherapeutics has higher revenue and earnings than Mana Capital Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/AProtalix BioTherapeutics$61.95M2.14$8.31M$0.0723.71 Do institutionals & insiders have more ownership in MAAQ or PLX? 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate MAAQ or PLX? Protalix BioTherapeutics has a consensus price target of $15.00, suggesting a potential upside of 803.61%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MAAQ or PLX more profitable? Mana Capital Acquisition has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Mana Capital Acquisition's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Protalix BioTherapeutics -21.03%-30.89%-11.74% SummaryProtalix BioTherapeutics beats Mana Capital Acquisition on 7 of the 11 factors compared between the two stocks. Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$48.67M$29.58M$2.58B$9.74BDividend YieldN/AN/A2.55%4.09%P/E RatioN/AN/A22.0425.97Price / SalesN/AN/A78.64123.18Price / CashN/AN/A23.2358.38Price / BookN/AN/A31.766.39Net IncomeN/AN/A$31.01M$265.66M7 Day Performance-2.67%-2.67%0.82%1.98%1 Month Performance-15.35%-15.35%1.56%1.33%1 Year Performance727.65%727.65%30.28%21.15% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$3.64+4.0%N/A+678.0%$48.67MN/A0.001PLXProtalix BioTherapeutics3.1083 of 5 stars$1.48-2.6%$15.00+913.5%+62.9%$117.82M$59.76M-11.38200News CoveragePositive NewsAnalyst RevisionAVTXAvalo Therapeutics3.3815 of 5 stars$9.02+0.8%$30.00+232.6%+8.3%$117.71M$440K0.0040News CoverageCLYMClimb Bio3.5946 of 5 stars$1.90+10.5%$9.00+373.7%N/A$116.55MN/A-2.719High Trading VolumeSAVACassava Sciences1.7961 of 5 stars$2.34-2.9%$2.00-14.5%-93.1%$116.42MN/A-0.9230ZURAZura Bio3.2499 of 5 stars$1.66-3.5%$14.17+753.4%-43.8%$113.50MN/A-2.373News CoverageAnalyst ForecastAnalyst RevisionCRDLCardiol Therapeutics2.6452 of 5 stars$1.31-2.2%$8.00+510.7%-42.6%$112.17MN/A-3.8520Positive NewsSPROSpero Therapeutics3.7936 of 5 stars$1.91-3.5%$5.00+161.8%+36.3%$111.43M$34.09M-1.95150IMRXImmuneering3.6363 of 5 stars$3.76+23.7%$13.25+252.4%+313.4%$110.41M$320K-1.9960News CoverageHigh Trading VolumeLIMNLiminatus PharmaN/A$4.00-2.9%N/AN/A$107.18MN/A0.00N/AGap UpZNTLZentalis Pharmaceuticals1.8037 of 5 stars$1.59+7.4%$8.20+415.7%-43.3%$106.76M$67.43M-0.70160High Trading Volume Related Companies and Tools Related Companies PLX Alternatives AVTX Alternatives CLYM Alternatives SAVA Alternatives ZURA Alternatives CRDL Alternatives SPRO Alternatives IMRX Alternatives LIMN Alternatives ZNTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAAQ) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access